Advertisement
Advertisement
Pfizer
TOPIC
 / company

Pfizer

Pfizer
Pfizer
The latest news, analysis and opinion on Pfizer. In-depth analysis, industry insights and expert opinion.
Chairman / President
Albert Bourla
CEO / Managing Director
Albert Bourla
CFO / Finance Director
Dave Denton
Industry
Pharmaceuticals
Website
pfizer.com
Headquarters address
235 East 42nd Street, New York, NY 10017, United States
Stock Code
NYSE:PFE
Year founded
1849
LATEST China Science NEWS

China’s asteroid hunter nears target after 400 days, though size is a surprise

videocam
China’s Tianwen-2 probe, which lifted off on May 29, 2025, has come within 20km of its target, according to CNSA. The mission aims to sample 2016 HO3 and study the main-belt comet 311P. Photo: Xinhua

Why China’s technical schools offer both hope and despair for jobless college grads

videocam
As more Chinese university graduates turn to vocational schools to improve their job prospects, some say their experience has not provided a straight path to a desired job. Photo: VCG via Getty Images

China rare earth industry has critical weakness, study finds

47
A mine in Baotou, Inner Mongolia, a part of China’s vast rare earth mining industry. But new study says the country’s “international patent layout remains insufficient”. Photo: AP

Energy scientist Chen Peipei leaves Cambridge to build her own lab in Hong Kong

videocam
22
Chen Peipei attends the Global Sustainable Development Congress 2026 in Jakarta in June. Photo: Handout

China offers sea cable detection tech to clients in Middle East, Europe and Asia

videocam
China aims to secure its position in the marine equipment sector by exporting advanced robots designed for locating underwater cables, official science daily says. Photo: Getty Images
MORE China Science NEWS
In focus: Chinese biotech firms such as Jiangsu Hengrui Pharmaceutical are navigating growing geopolitical scrutiny as cross-border licensing deals continue to expand. Photo: Shutterstoc
China’s private sector

Bigger, fewer, tougher: the new era of China-US biotech partnerships

China’s biotech boom continues to attract Western drug makers even as Washington expands investment and technology controls.

China’s private sector

Which company could become the Chinese Pfizer? Here are analysts’ top picks

Biomedicine: Companies

China’s Innovent Biologics signs US$10.5b Pfizer deal for 12 cancer drug trials

videocam
Hong Kong economy

Which global firms are being attracted by Hong Kong’s strategic enterprise scheme?

The South China Morning Post examines 22 firms opening or expanding in the city, with HK$73 billion in investment and 25,000 jobs expected.

Pfizer, a leading global research‑based pharmaceutical and biotechnology company, is among the biggest names in the latest cohort. Photo: Reuters
Hong Kong economy

Pfizer, Amgen among 22 majors spreading wings in Hong Kong under investment push

Sixth batch under OASES initiative also features Boehringer Ingelheim, Hengrui and Haya, with Didi and AutoFlight joining transport push.

China’s private sector

Eli Lilly boosts China footprint with US$3 billion plan to expand supply chain

US firm is strengthening its China operations amid an intensifying expansion race with other pharmaceutical giants.

Advertisement
Advertisement
Advertisement
Medicine

‘Save a fortune’: Trump unveils TrumpRx discount drug site

New platform connects American patients directly to drug makers with promised price cuts on popular medications like Ozempic.

US President Donald Trump at the TrumpRx website launch. Photo: EPA
Biomedicine: Industry Trends

China could approve first AI-designed drug next year, Merck executive says

AI and genetics are creating a ‘seismic shift’ in the pharmaceutical business, experts on Asian Financial Forum panel say.

Biomedicine: Industry Trends

Harbour BioMed stake in US drug developer shows Chinese firms’ growing clout

Latest example of Chinese drug maker acquiring equity in overseas partner shows they are becoming true development partners, analysts say.

Made in China 2025

Chinese biotechs strike a record US$136 billion in out-licensing deals in 2025

Chinese drug makers signed 157 out-licensing deals with global pharmaceutical firms last year versus 94 a year earlier.

Last year, China approved 76 innovative drugs, including 47 chemical drugs and 23 biologics. Photo: Shutterstock
Made in China 2025

Meow or never: China’s pudgy pets spark race for weight-loss drugs

Fosun and Huadong biotech labs eye feline obesity drugs as owners weigh cuteness against health risks.

The total pet population in China reached 430 million in 2024, with nearly one-third of urban cats classified as obese, according to the China Pet Industry Association. Photo: Shutterstock
United States

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

Made in China 2025

Chinese biotech Scizeng’s global licensing deal to yield up to US$1.44 billion

Yarrow Bioscience gets exclusive global rights for the GenSci098 therapy to treat thyroid eye disease and Graves’ disease.

Made in China 2025

China’s Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer

Yao Pharma’s deal with the US pharmaceutical giant underscores China’s growing role in global biotech licensing.

The collaboration is “another significant milestone in Fosun Pharma’s strategy of innovation and internationalisation”, according to the company. Photo: Reuters
China economy

Opinion | How China engineered the rapid rise of its drug innovation industry

A market once dominated by generics is now an AI-powered pharmaceutical hub drawing billion-dollar investments from the likes of Pfizer and GSK.

videocam
A worker checks the position of a feeding tray in a pharmaceutical manufacturing facility at the Hengrui Biomedical Industrial Park in Lianyungang in Jiangsu province, on December 13, 2021. Photo: Getty Images
Science

Have Chinese chemists cracked the code for cheaper medicine production?

The research team’s straightforward alternative to expensive, complex and dangerous production method hailed as ‘Nobel Prize level’.

videocam
18
US-China relations

Xi-Trump summit opens window of opportunity for US firms at China import expo

More US companies are expected at this year’s China International Import Expo, hoping to secure deals in wake of bilateral summit.

videocam
Advertisement
Advertisement
Advertisement
Hong Kong economy

Letters | How Hong Kong can help Chinese drug makers go global

Readers discuss opportunities from medical innovation, tech standards in Hong Kong, and how to stop people treating corals like inanimate objects.

A view of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone on April 24. Photo: Edmond So
Donald Trump

Trump says Pfizer will cut drug prices for tariff relief

The White House is also planning a direct-to-consumer website called TrumpRx for Americans to buy medication.

Singapore

Singapore’s drug makers may be shielded from US tariffs: Deputy PM Gan

The city state may pursue a ceiling on tariff rates similar to deals that Washington has with other countries, Deputy PM Gan Kim Yong adds.

Biomedicine: Companies

Pfizer’s Metsera acquisition to spur Chinese search for new weight drugs

The deal, worth up to US$7.3 billion, will encourage ongoing investment by mainland players but not draw in new rivals, analysts say.

The Pfizer deal is not good news for Chinese firms developing weight-loss drugs with the aim of reducing injections, an analyst says. Photo: Shutterstock
Biomedicine: Companies

China’s Jiangsu Hengrui signs licensing deal with Braveheart Bio for heart drug

The licensing deal for the HRS-1893 innovative drug could fetch as much as US$1.01 billion in milestone payments.

The headquarters of Jiangsu Hengrui Pharmaceutical in Lianyungang Economic and Technological Development Zone, in Jiangsu province. Photo: Costfoto/Future Publishing via Getty Images
Made in China 2025

China vows stronger biotech support as deals with global drug makers surge

Chinese developers signed one-third of all agreements with global drug firms in the first half of 2025.

Biomedicine: Companies

Pfizer, Chinese biotech firm 3SBio complete licensing deal for cancer drug

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity investment in 3SBio.

European Union

EU chief Ursula von der Leyen easily survives parliament no-confidence vote

EU lawmakers dismissed allegations against Ursula von der Leyen regarding private text messaging with Pfizer’s CEO, misuse of funds, and election interference.

European Commission President Ursula von der Leyen survived a no-confidence vote amid far-right tensions and corruption allegations. Photo: EPA
Singapore

Singapore prioritising pharmaceutical supply chains in US tariff talks

Pharmaceutical supply chains account for more than 10 per cent of Singapore’s exports to the US.

Photo: Shutterstock
CSPC Pharmaceutical

Chinese biotech’s mega drug-licensing deals with multinationals surge

Such deals allow Chinese firms to profit while minimising capital outlays, but also carry risks, law firm says.

Biomedicine: Companies

Chinese biotech firm secures Pfizer deal despite trade tensions

Pfizer will produce the drug, which targets lung and colorectal cancers, in the US and take a US$100 million stake in China’s 3SBio.

videocam
Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement